Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Allopurinol
Drug ID BADD_D00076
Description Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942]. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942]. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705]. It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].
Indications and Usage Allopurinol is indicated in [FDA label]: 1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. 3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
Marketing Status approved
ATC Code M04AA01
DrugBank ID DB00437
KEGG ID D00224
MeSH ID D000493
PubChem ID 135401907
TTD Drug ID D04KYY
NDC Product Code 23155-694; 43063-975; 55154-5534; 60687-688; 62135-516; 66064-1043; 69967-009; 70710-1209; 70934-681; 71610-676; 72189-437; 43063-934; 55154-5454; 58118-1156; 60687-677; 60760-656; 61919-748; 63187-463; 0378-0181; 67296-1314; 68083-380; 68788-8364; 70199-031; 71610-194; 0603-2116; 51927-0070; 51927-1915; 16571-885; 16714-042; 16729-135; 43353-186; 51655-082; 0378-0137; 66267-665; 67544-313; 68071-2997; 68788-8458; 69967-008; 70199-016; 70518-3660; 70710-1210; 0603-2115; 71610-678; 63629-2113; 63739-410; 66064-1044; 68788-6323; 71610-681; 63552-151; 68108-0212; 51079-206; 51655-968; 53002-4821; 53489-157; 55111-729; 63739-796; 68071-2616; 68071-2660; 68788-7383; 70934-882; 71205-208; 71610-064; 0591-5544; 49452-0008; 65015-606; 66064-2100; 16571-883; 16714-041; 43353-501; 51655-523; 51655-782; 53002-4820; 55700-947; 62584-988; 63187-240; 63629-2112; 70771-1126; 0591-5543; 71610-253; 0615-8385; 57451-1166; 16714-576; 23155-693; 43063-976; 51655-945; 55154-7981; 60760-139; 62584-713; 63629-7908; 67457-187; 67457-978; 67544-736; 70199-033; 71205-377; 72162-1150; 0904-7041; 17351-0041; 36974-0018; 16571-884; 29300-349; 50090-5168; 51079-205; 61919-471; 62135-517; 63629-2111; 63629-8020; 65219-380; 67296-1265; 69315-291; 70518-1806; 70518-3289; 70771-1127; 70934-979; 71335-0467; 71335-1656; 71335-9634; 71610-197; 72189-417; 80425-0206; 0904-6572; 29300-350; 50090-4662; 68071-2926; 69315-292; 70199-032; 70518-3704; 71205-049; 71335-9641; 71335-9676; 72162-1149; 49711-0113; 63552-150; 65977-0124; 16714-577; 16729-134; 43063-935; 53489-156; 55700-935; 60760-134; 68788-8337; 68788-8424; 70199-015; 70518-0451; 71335-0112; 14445-001; 72375-0007; 50090-0044; 50090-5194; 55111-730; 55154-2338
UNII 63CZ7GJN5I
Synonyms Allopurinol | Uribenz | Allopurin | Allorin | Allpargin | Allural | Pan Quimica | Apulonga | Apurin | Atisuril | Bleminol | Caplenal | Capurate | Cellidrin | Embarin | Suspendol | Foligan | Hamarin | Lopurin | Lysuron | Jenapurinol | Milurit | Milurite | Novopurol | Uripurinol | Urosin | Urtias | Xanthomax | Uridocid | Xanturic | Zygout | Zyloprim | Zyloric | Pureduct | Purinol | Progout | Remid | Rimapurinol | Roucol | Tipuric | Allohexal | Allohexan | Alloprin
Chemical Information
Molecular Formula C5H4N4O
CAS Registry Number 315-30-0
SMILES C1=NNC2=C1C(=O)NC=N2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.010--Not Available
Bone marrow eosinophilic leukocyte count increased13.01.08.001--Not Available
Exfoliative rash23.03.07.006--Not Available
Bone marrow failure01.03.03.005--
Liver injury09.01.07.022; 12.01.17.012--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Acute kidney injury20.01.03.016--
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.021--Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Symblepharon06.06.02.012--Not Available
Parophthalmia06.04.11.003--Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.035--Not Available
SJS-TEN overlap23.03.01.041; 12.03.01.069; 11.07.01.030; 10.01.01.043--Not Available
Therapeutic response shortened08.06.01.062--Not Available
The 9th Page    First    Pre   9    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene